Deals
Partnerships decreased in the pharmaceutical industry in H2 2021
The proportion of pharmaceutical companies hiring for cloud related positions rose to a year-high in August 2021, with 42.7% of the companies included in our analysis recruiting for at least one such position.
Partnerships in the pharmaceutical sector have seen a decrease of 18% from H2 2020 to H2 2021, an analysis of GlobalData's deals database reveals.
Powered by
In the second half of 2021 the number of partnerships decreased by 18% from the same period in 2020.
This marks a deceleration in growth from the 11.7% decrease in deals that occurred in H1 2021 relative to the same period a year earlier.
During second half of 2021, partnerships accounted for 31.5% of all deals taking place in the sector. This represents an increase from the figure of 30.3% in second half of 2020.
GlobalData's deals database is a comprehensive repository that looks at mergers, acquisitions, venture financing, equity offerings, asset transactions, partnerships and debt offerings taking place daily between thousands of companies across the world.
The database details key deal information, such as deal summary, deal rationale, deal financials, parties involved, advisors and deal payment modes.
By tracking the proportion of various types of deals in each sector we can gauge which sectors are seeing growth and where others are struggling.
The highest value partnership announced in 2021 (where the deal value was known), was the co-Development agreement between Alector and GSK. The deal is set to be worth $2,200 million.
